MAIA Biotechnology (NYSEAMERICAN:MAIA) Announces Quarterly Earnings Results

MAIA Biotechnology (NYSEAMERICAN:MAIA) issued its earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.21, Zacks reports.

MAIA Biotechnology Price Performance

MAIA Biotechnology stock traded down $0.20 during midday trading on Thursday, hitting $2.19. 128,765 shares of the company’s stock were exchanged, compared to its average volume of 286,300. MAIA Biotechnology has a 12 month low of $0.82 and a 12 month high of $5.99. The stock has a market cap of $52.36 million, a price-to-earnings ratio of -1.57 and a beta of 0.32.

Insider Transactions at MAIA Biotechnology

In other MAIA Biotechnology news, Director Cristian Luput acquired 22,133 shares of MAIA Biotechnology stock in a transaction that occurred on Friday, November 1st. The stock was bought at an average price of $2.51 per share, with a total value of $55,553.83. Following the completion of the purchase, the director now directly owns 389,483 shares of the company’s stock, valued at approximately $977,602.33. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 36.98% of the company’s stock.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.